Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334361 | 0.85 | MAOB (0.55) | APPADRA2AADRA2BADRA2CMRGPRX4 | |
| SCHEMBL5327582 | 0.80 | DRD2 (0.54) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5045262 | 0.77 | MAOB (0.57) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| SCHEMBL3077665 | 0.77 | HRH3 (0.67) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5040459 | 0.76 | MAOB (0.56) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| SCHEMBL27735405 | 0.73 | APP (0.77) | APPRAB9AL3MBTL1LMNAGAA | |
| SCHEMBL11961606 | 0.71 | MAOB (0.54) | NPC1RAB9APOLBGFERPAX8 | |
| SCHEMBL3898063 | 0.71 | HTR2C (0.66) | NPC1RAB9APOLBGFERPAX8 | |
| SCHEMBL29097961 | 0.71 | MAOB (0.52) | NPC1RAB9AHRH3 | |
| SCHEMBL30199621 | 0.71 | MAOB (0.52) | NPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149728-A2 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149728-A2 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | HTR2B, HTR2A, HTR3B | APP 2527/4885DRD2 72/4885DRD1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.